Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 277-286

  Freire, M P ^a   Pierrotti, L C ^a   Filho, H H C ^b   Ibrahim, K Y ^a   Magri, A S G K ^a   Bonazzi, P R ^a   Hajar, L ^a   Diz, M P E ^c   Pereira, J ^c   Hoff, P M ^b,c   Abdala, E ^a,d  

^a Instituto do Cancer do Estado de São Paulo   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^d NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER PATIENT; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CONTROLLED STUDY; DEVICE INFECTION; DIGESTIVE SYSTEM DISEASE; DISEASE SEVERITY; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS; HUMAN; IN VITRO STUDY; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID TUMOR; SURGICAL INFECTION; URINARY TRACT INFECTION; COMPLICATION; CROSS INFECTION; ENZYMOLOGY; KLEBSIELLA INFECTION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CROSS INFECTION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS;

EID: 84921766986     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2233-5     Document Type: Article

References (46)

1. Schelenz S, Nwaka D, Hunter PR (2013) Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother 68(6):1431–1438
2. Nordmann P, Cuzon G, Naas T (2009) The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236
3. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC (2001) Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45(4):1151–1161
4. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796
5. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO (2009) Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 30:1180–1185
6. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y (2008) Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 52:1028–1033
7. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP (2008) Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099–1106
8. Kwak YG, Choi SH, Choo EJ, Chung JW, Jeong JY, Kim NJ, Woo JH, Ryu J, Kim YS (2005) Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 11:165–168
9. Orsi GB, Bencardino A, Vena A, Carattoli A, Venditti C, Falcone M, Giordano A, Venditti M (2013) Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection 41(1):61–67
10. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y (2008) Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 52:1413–1418
11. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, Tsioka A, Roilides E, Sofianou D, Gritsi-Gerogianni N (2010) Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 31(12):1250–1256
12. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H (2010) An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50:364–373
13. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A (2011) Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798–1803
14. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950
15. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M (2013) Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13(10):2619–2633
16. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, Barbosa V, Abboud CS (2012) Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 14(2):198–205
17. Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ (2013) Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54(4):799–806
18. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332
19. Clinical and Laboratory Standards Institute (CLSI) (2012) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S22. CLSI, Wayne
20. U.S. Food and Drug Administration (FDA). Tygacil® label information. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s027lbl.pdf
21. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2011) Breakpoint tables for interpretation of MICs and zone diameters, version 1.3, January 5, 2011. Available online at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf
22. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31
23. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM (2006) Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 25(1):1–7
24. Velasco E, Soares M, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM (2004) Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. Eur J Clin Microbiol Infect Dis 23(8):596–602
25. Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, Andrianaki AM, Falagas ME (2013) A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 21(9):2521–2526
26. Lin YT, Liu CJ, Fung CP, Tzeng CH (2011) Nosocomial Klebsiella pneumoniae bacteraemia in adult cancer patients—characteristics of neutropenic and non-neutropenic patients. Scand J Infect Dis 43(8):603–608
27. Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH (2012) Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case–control study. J Microbiol Immunol Infect 45(2):113–119
28. Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS (2013) Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 92(4):533–541
29. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56(4):2108–2113
30. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX (2013) Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case–control analysis. Infection 42(2):309–316
31. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580–637
32. Ghanem G, Hachem R, Jiang Y, Chemaly RF, Raad I (2007) Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 28(9):1054–1059
33. Huh K, Kang CI, Kim J, Cho SY, Ha YE, Joo EJ, Chung DR, Lee NY, Peck KR, Song JH (2013) Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer. Diagn Microbiol Infect Dis 78(2):172–177
34. Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH (2013) Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents 42(5):403–409
35. Pankey GA, Ashcraft DS (2011) Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70(4):561–564
36. Clock SA, Tabibi S, Alba L, Kubin CJ, Whittier S, Saiman L (2013) In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 76(3):343–346
37. Deris ZZ, Yu HH, Davis K, Soon RL, Jacob J, Ku CK, Poudyal A, Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Paterson DL, Velkov T, Li J, Nation RL (2012) The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56(10):5103–5112
38. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D (2005) Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56(1):128–132
39. Landman D, Georgescu C, Martin DA, Quale J (2008) Polymyxins revisited. Clin Microbiol Rev 21(3):449–465
40. Kaiser RM, Castanheira M, Jones RN, Tenover F, Lynfield R (2013) Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007–2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 76(3):356–360
41. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP (2013) Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57(4):524–531
42. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J (2013) Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 68(3):674–677
43. Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, Mehta SA (2013) Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 57(11):5394–5397
44. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, Kassis I (2013) Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 83(4):307–313
45. Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, Fianchi L, Leone F, Fadda G, Cauda R, Pagano L (2009) Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 64(3):320–326
46. Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra A, Boix L, Domingo-Domenech E, Calvo M, Carratalà J (2014) Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer 22(3):603–610